NYSE · AIM

AIM ImmunoTech Inc.

Closing price · Nov 13, 2026 $0.1436
Last insider buy price $0.15 Paid by CEO & President, Director Thomas Equels on Nov 11, 2026 (Form 4). Not today's price.

Latest quarter · ended Sep 30, 2026

Sales slipped and cash got weaker

descriptionFiled Nov 12, 2026
Revenue growthShrinking
−15.4%
Quarter ended Dec 31, 2024: −30.8% sales vs. a year beforeQuarter ended Mar 31, 2025: −60.0% sales vs. a year beforeQuarter ended Jun 30, 2025: −50.0% sales vs. a year beforeQuarter ended Sep 30, 2025: −25.7% sales vs. a year beforeQuarter ended Dec 31, 2025: −53.3% sales vs. a year beforeQuarter ended Mar 31, 2026: +37.5% sales vs. a year beforeQuarter ended Jun 30, 2026: +4.0% sales vs. a year beforeQuarter ended Sep 30, 2026: −15.4% sales vs. a year before
Dec '24Sep '26
$22K vs. $26K a year ago
Cash from operationsBetter
−$2.93M
Quarter ended Dec 31, 2024: −$3.96M cash from operationsQuarter ended Mar 31, 2025: −$2.36M cash from operationsQuarter ended Jun 30, 2025: −$1.53M cash from operationsQuarter ended Sep 30, 2025: −$5.08M cash from operationsQuarter ended Dec 31, 2025: −$1.99M cash from operationsQuarter ended Mar 31, 2026: −$2.72M cash from operationsQuarter ended Jun 30, 2026: −$4.59M cash from operationsQuarter ended Sep 30, 2026: −$2.93M cash from operations
Dec '24Sep '26
vs. −$5.08M a year ago
Share countDiluting
+1299.2%
Quarter ended Dec 31, 2024: 72.29M sharesQuarter ended Mar 31, 2025: 76.42M sharesQuarter ended Jun 30, 2025: 2.71M sharesQuarter ended Sep 30, 2025: 2.85M sharesQuarter ended Dec 31, 2025: 8.15M sharesQuarter ended Mar 31, 2026: 14.56M sharesQuarter ended Jun 30, 2026: 30.44M sharesQuarter ended Sep 30, 2026: 39.92M shares
Dec '24Sep '26
39.92M shares vs. 2.85M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Buying Insiders: as of Nov 13 Funds: as of Jun 30, 2026
−1000+100 +100
  • group
    1 insider bought in the last 30 days. $31K in open-market buys, Oct 22–Nov 11.
  • info
    No real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

19 funds report owning AIM, up from 17

Holdings as of Jun 30, 2026
New4
Added5
Held9
Trimmed1
Sold out2

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale
CEOCFOOther officersDirectorsDecJanFebMarAprMayJunJulAugSepOctNovStock grant · Feb 5 · $3.44KCode C · Mar 12 · 25,000 shCode C · Mar 12 · 25,000 shOpen-market buy · Sep 14 · $1.3KOpen-market buy · Sep 15 · $4.84KOpen-market buy · Sep 16 · $2.31KOpen-market buy · Sep 17 · $5.04KOpen-market buy · Oct 22 · $5.09KOpen-market buy · Oct 23 · $5.07KOpen-market buy · Nov 6 · $5.18KOpen-market buy · Nov 9 · $5.07KOpen-market buy · Nov 10 · $5.38KOpen-market buy · Nov 11 · $5.21K
CEOCFOOther officersDirectorsJunJulAugSepOctNovOpen-market buy · Sep 14 · $1.3KOpen-market buy · Sep 15 · $4.84KOpen-market buy · Sep 16 · $2.31KOpen-market buy · Sep 17 · $5.04KOpen-market buy · Oct 22 · $5.09KOpen-market buy · Oct 23 · $5.07KOpen-market buy · Nov 6 · $5.18KOpen-market buy · Nov 9 · $5.07KOpen-market buy · Nov 10 · $5.38KOpen-market buy · Nov 11 · $5.21K

Last 6 months. A wider screen shows 12.

Showing 10 real trades. Hidden: 1 stock grant. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.

Real trades, newest first

Nov 11 Thomas Equels CEO & President, Director Open-market buy $5.21K 35,000 sh at $0.15
Nov 10 Thomas Equels CEO & President, Director Open-market buy $5.38K 39,000 sh at $0.14
Nov 9 Thomas Equels CEO & President, Director Open-market buy $5.07K 31,298 sh at $0.16
Nov 6 Thomas Equels CEO & President, Director Open-market buy $5.18K 33,050 sh at $0.16
Oct 23 Thomas Equels CEO & President, Director Open-market buy $5.07K 31,675 sh at $0.16
Oct 22 Thomas Equels CEO & President, Director Open-market buy $5.09K 31,250 sh at $0.16
Sep 17 Thomas Equels CEO & President, Director Open-market buy $5.04K 24,000 sh at $0.21
Sep 16 Thomas Equels CEO & President, Director Open-market buy $2.31K 11,000 sh at $0.21
Sep 15 Thomas Equels CEO & President, Director Open-market buy $4.84K 22,000 sh at $0.22
Sep 14 Thomas Equels CEO & President, Director Open-market buy $1.3K 5,900 sh at $0.22

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in AIM

As of Jun 30, 2026
FundOwnsValueChange
Jane Street Group, LLC2.0%$229K+3930%
Virtu Financial LLC0.3%$35K+144%
Morgan Stanley0.1%$14.4K+5787%
Geode Capital Management, LLC0.1%$13.1K+54%
Goldman Sachs Group Inc0.1%$9.21KNew

"Owns" is shares reported divided by shares outstanding.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast